Literature DB >> 17928431

Use of synthetic derivatives to determine the minimal active structure of cytokine-inducing lipoteichoic acid.

Susanne Deininger1, Ignacio Figueroa-Perez, Stefanie Sigel, Andreas Stadelmaier, Richard R Schmidt, Thomas Hartung, Sonja von Aulock.   

Abstract

Lipoteichoic acid (LTA) from gram-positive bacteria is the counterpart to lipopolysaccharide from gram-negative bacteria. LTA, which activates Toll-like receptor 2 (TLR2), induces a unique cytokine and chemokine pattern. The chemical synthesis of LTA proved its immunostimulatory properties. To determine the minimal active structure of LTA, we reduced synthetic LTA in a number of steps down to the synthetic anchor and employed these molecules to stimulate interleukin-8 (IL-8) release in human whole blood. Ten times more of the synthetic structures with four to six d-alanine-substituted polyglycerophosphate units (50 nM) than of the native LTA preparation was required to induce IL-8 release. A further reduction to three backbone units with two or no d-alanine residues resulted in cytokine induction only from 500 nM. The synthetic anchor was not able to induce IL-8 release even at 5 muM. When the LTA derivatives were used at 500 nM, they induced increasing levels of IL-8 and tumor necrosis factor alpha with increasing elongation of the backbone. Peritoneal macrophages were less responsive than human blood to the synthetic structures. Therefore, TLR2 dependency could be shown only with cells from TLR2-deficient mice for the two largest synthetic structures. This was confirmed by using TLR2-transfected HEK 293 cells. Taken together, these data indicate that although the synthetic anchor (which, unlike the native anchor, contains only myristic acid) cannot induce cytokine release, the addition of three backbone units, even without d-alanine substituents, confers this ability. Lengthening of the chain with d-alanine-substituted backbone units results in increased cytokine-inducing potency and a more sensitive response.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17928431      PMCID: PMC2168384          DOI: 10.1128/CVI.00007-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  17 in total

1.  [Effects of bacterial toxins; biochemical analysis of inflammation].

Authors:  O WESTPHAL; O LUDERITZ; W KEIDERLING
Journal:  Zentralbl Bakteriol Orig       Date:  1952-06

2.  Cytokine induction by purified lipoteichoic acids from various bacterial species--role of LBP, sCD14, CD14 and failure to induce IL-12 and subsequent IFN-gamma release.

Authors:  Corinna Hermann; Ingo Spreitzer; Nicolas W J Schröder; Siegfried Morath; Martin D Lehner; Werner Fischer; Christine Schütt; Ralf R Schumann; Thomas Hartung
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

3.  Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations.

Authors:  Siegfried Morath; Armin Geyer; Ingo Spreitzer; Corinna Hermann; Thomas Hartung
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

5.  Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus activates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.

Authors:  Nicolas W J Schröder; Siegfried Morath; Christian Alexander; Lutz Hamann; Thomas Hartung; Ulrich Zähringer; Ulf B Göbel; Joerg R Weber; Ralf R Schumann
Journal:  J Biol Chem       Date:  2003-02-19       Impact factor: 5.157

6.  CD36 is a sensor of diacylglycerides.

Authors:  Kasper Hoebe; Philippe Georgel; Sophie Rutschmann; Xin Du; Suzanne Mudd; Karine Crozat; Sosathya Sovath; Louis Shamel; Thomas Hartung; Ulrich Zähringer; Bruce Beutler
Journal:  Nature       Date:  2005-02-03       Impact factor: 49.962

7.  Essential role of MD-2 in LPS responsiveness and TLR4 distribution.

Authors:  Yoshinori Nagai; Sachiko Akashi; Masakazu Nagafuku; Masato Ogata; Yoichiro Iwakura; Shizuo Akira; Toshio Kitamura; Atsushi Kosugi; Masao Kimoto; Kensuke Miyake
Journal:  Nat Immunol       Date:  2002-06-10       Impact factor: 25.606

8.  MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.

Authors:  R Shimazu; S Akashi; H Ogata; Y Nagai; K Fukudome; K Miyake; M Kimoto
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

9.  Structure-function relationship of cytokine induction by lipoteichoic acid from Staphylococcus aureus.

Authors:  S Morath; A Geyer; T Hartung
Journal:  J Exp Med       Date:  2001-02-05       Impact factor: 14.307

10.  Synthetic lipoteichoic acid from Staphylococcus aureus is a potent stimulus of cytokine release.

Authors:  Siegfried Morath; Andreas Stadelmaier; Armin Geyer; Richard R Schmidt; Thomas Hartung
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  12 in total

1.  A subclass of acylated anti-inflammatory mediators usurp Toll-like receptor 2 to inhibit neutrophil recruitment through peroxisome proliferator-activated receptor gamma.

Authors:  Elizabeth M Long; Alexander C Klimowicz; Heitor A Paula-Neto; Brandie Millen; Donna-Marie McCafferty; Paul Kubes; Stephen M Robbins
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-19       Impact factor: 11.205

2.  Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation.

Authors:  Janine K Tom; Rock J Mancini; Aaron P Esser-Kahn
Journal:  Chem Commun (Camb)       Date:  2013-10-25       Impact factor: 6.222

3.  Role of Lipoteichoic Acid from the Genus Apilactobacillus in Inducing a Strong IgA Response.

Authors:  Chiaki Matsuzaki; Tsukasa Shiraishi; Tai-Ying Chiou; Yukari Nakashima; Yasuki Higashimura; Shin-Ichi Yokota; Kenji Yamamoto; Tomoya Takahashi
Journal:  Appl Environ Microbiol       Date:  2022-04-05       Impact factor: 5.005

4.  Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides.

Authors:  Hemamali J Warshakoon; Mark R Burns; Sunil A David
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

5.  Lipoteichoic acid from Staphylococcus aureus exacerbates respiratory disease in porcine respiratory coronavirus-infected pigs.

Authors:  Kalina Atanasova; Steven Van Gucht; Filip Barbé; Luc Duchateau; Kristien Van Reeth
Journal:  Vet J       Date:  2010-04-20       Impact factor: 2.688

6.  The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects.

Authors:  Z Abi Khattar; A Rejasse; D Destoumieux-Garzón; J M Escoubas; V Sanchis; D Lereclus; A Givaudan; M Kallassy; C Nielsen-Leroux; S Gaudriault
Journal:  J Bacteriol       Date:  2009-09-18       Impact factor: 3.490

7.  Soluble human TLR2 ectodomain binds diacylglycerol from microbial lipopeptides and glycolipids.

Authors:  Maximiliano J Jiménez-Dalmaroni; Catherine M Radcliffe; David J Harvey; Mark R Wormald; Petra Verdino; Gary D Ainge; David S Larsen; Gavin F Painter; Richard Ulevitch; Bruce Beutler; Pauline M Rudd; Raymond A Dwek; Ian A Wilson
Journal:  Innate Immun       Date:  2014-03-03       Impact factor: 2.680

8.  Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species.

Authors:  Amy Barton Pai; Heena Patel; Alexander J Prokopienko; Hiba Alsaffar; Nancy Gertzberg; Paul Neumann; Anjoli Punjabi; Arnold Johnson
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240

9.  Immunomodulatory mechanisms of lactobacilli.

Authors:  Jerry M Wells
Journal:  Microb Cell Fact       Date:  2011-08-30       Impact factor: 5.328

10.  Systematic review of membrane components of gram-positive bacteria responsible as pyrogens for inducing human monocyte/macrophage cytokine release.

Authors:  Christoph Rockel; Thomas Hartung
Journal:  Front Pharmacol       Date:  2012-04-17       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.